ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,546,144 | +491.4% | 273,779 | +237.7% | 0.00% | – |
| Q3 2023 | $430,535 | -34.3% | 81,080 | +36.0% | 0.00% | – |
| Q2 2023 | $655,765 | 0.0% | 59,615 | 0.0% | 0.00% | – |
| Q1 2023 | $655,765 | +31.4% | 59,615 | +76.8% | 0.00% | – |
| Q4 2022 | $498,997 | -99.9% | 33,716 | +76.5% | 0.00% | – |
| Q3 2022 | $365,001,000 | -42.9% | 19,100 | -36.3% | 0.00% | – |
| Q2 2022 | $638,703,000 | +10.6% | 29,972 | 0.0% | 0.00% | – |
| Q1 2022 | $577,261,000 | -7.1% | 29,972 | 0.0% | 0.00% | – |
| Q4 2021 | $621,619,000 | -13.2% | 29,972 | 0.0% | 0.00% | – |
| Q3 2021 | $716,031,000 | -12.5% | 29,972 | 0.0% | 0.00% | – |
| Q2 2021 | $817,936,000 | +33.4% | 29,972 | +41.4% | 0.00% | – |
| Q1 2021 | $613,316,000 | – | 21,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $128,526,634 | 7.99% |
| Saturn V Capital Management LP | 487,179 | $8,787,113 | 7.29% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $44,400 | 4.96% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $8,421,807 | 3.66% |
| Logos Global Management LP | 1,400,000 | $20,720,000 | 2.43% |
| Rubric Capital Management LP | 2,742,519 | $40,589,281 | 1.77% |
| 1492 Capital Management LLC | 174,546 | $2,583,281 | 1.67% |
| AlphaCentric Advisors LLC | 78,500 | $1,161,800 | 1.15% |
| MPM BioImpact LLC | 262,069 | $3,878,621 | 1.01% |
| Orbimed Advisors | 2,460,108 | $36,409,598 | 0.70% |